Skip to main content

Advertisement

SpringerLink
Log in

Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m2 on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4 weeks. Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival (OS) were 5.6 and 8.7 months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3–4 neutropenia occurred in 30% of the patients and 7% of patients presented with febrile neutropenia. Grade 3–4 diarrhea occurred in 21% of the patients. A subgroup consisting of patients ≥65 years of age had outcomes similar to the younger group <65 years of age. The objective RR was 72% in the patients <65 years of age and 77% in the patients ≥65 years of age (P = .738). The median PFS and OS (<65 years vs. ≥65 years) were 5.3 vs. 5.6 months (P = .835) and 9.0 vs. 8.7 months (P = .648), respectively. The combination of irinotecan and carboplatin is active and tolerable in patients with ED-SCLC. This regimen could be considered as a treatment option for patients of advanced age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Govindan R, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.

    Article  PubMed  Google Scholar 

  2. Murray N, Turrisi AT 3rd. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol. 2006;1:270–8.

    PubMed  Google Scholar 

  3. Rowland KM Jr, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996;14:135–41.

    PubMed  CAS  Google Scholar 

  4. Roth BJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–91.

    PubMed  CAS  Google Scholar 

  5. Ihde DC, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12:2022–34.

    PubMed  CAS  Google Scholar 

  6. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol. 1996;23:21–6.

    PubMed  CAS  Google Scholar 

  7. Masuda N, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–9.

    PubMed  CAS  Google Scholar 

  8. Kudoh S, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol. 1998;16:1068–74.

    CAS  Google Scholar 

  9. Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.

    Article  PubMed  CAS  Google Scholar 

  10. Bishop JF, et al. Carboplatin (CBDCA, JM-8) and VP-16–213 in previously untreated patients with small-cell lung cancer. J Clin Oncol. 1987;5:1574–8.

    PubMed  CAS  Google Scholar 

  11. Skarlos DV, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994;5:601–7.

    PubMed  CAS  Google Scholar 

  12. Calvert AH, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–56.

    PubMed  CAS  Google Scholar 

  13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.

    Article  PubMed  CAS  Google Scholar 

  14. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    CAS  Google Scholar 

  15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.

    Article  PubMed  CAS  Google Scholar 

  16. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. Am J Med. 1969;46:516–25.

    Article  PubMed  CAS  Google Scholar 

  17. Johnson BE, Janne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:309–22.

    Article  PubMed  Google Scholar 

  18. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol. 2004;49:119–33.

    Article  PubMed  Google Scholar 

  19. Mascaux C, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30:23–36.

    Article  PubMed  CAS  Google Scholar 

  20. Fukuoka M, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83:855–61.

    Article  PubMed  CAS  Google Scholar 

  21. Schmittel A, Keilholz U. Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer? Nat Clin Pract Oncol. 2009;6:134–5.

    Article  PubMed  CAS  Google Scholar 

  22. Hanna N, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.

    Article  PubMed  CAS  Google Scholar 

  23. Lara PN Jr, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–5.

    Article  PubMed  CAS  Google Scholar 

  24. Miyamoto H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology. 1992;49:431–5.

    Article  PubMed  CAS  Google Scholar 

  25. Niell HB, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23:3752–9.

    Article  PubMed  CAS  Google Scholar 

  26. Dimitroulis J, et al. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study. Oncol Rep. 2008;20:879–84.

    PubMed  CAS  Google Scholar 

  27. Eckardt JR, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24:2044–51.

    Article  PubMed  CAS  Google Scholar 

  28. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer. 1998;82:2166–72.

    Article  PubMed  CAS  Google Scholar 

  29. DeVore RF, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1999;17:2710–20.

    PubMed  CAS  Google Scholar 

  30. Kinoshita A, et al. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer. 2006;94:1267–71.

    Article  PubMed  CAS  Google Scholar 

  31. Sohn JH, et al. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer. 2006;54:365–70.

    Article  PubMed  Google Scholar 

  32. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am. 2000;14:193–212. x–xi.

    Article  PubMed  CAS  Google Scholar 

  33. Langer CJ, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:173–81.

    PubMed  Google Scholar 

  34. Li J, Chen P, Dai CH, Li XQ, Bao QL. Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study. Geriatr Gerontol Int. 2009;9:172–82.

    Article  PubMed  CAS  Google Scholar 

  35. Okamoto H, et al. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cancer. 2006;53:197–203.

    Article  PubMed  Google Scholar 

  36. Chen G, et al. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009;27:1401–4.

    Article  PubMed  CAS  Google Scholar 

  37. Schmittel A, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006;17:663–7.

    Article  PubMed  CAS  Google Scholar 

  38. Hermes A, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26:4261–7.

    Article  PubMed  CAS  Google Scholar 

  39. Schmittel A, et al. Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial. J Clin Oncol. 2009;27:abstr 8029.

    Google Scholar 

  40. Spigel DR, et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol. 2007;2:854–61.

    Article  PubMed  Google Scholar 

  41. Spigel DR, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol. 2009;4:1555–60.

    Article  PubMed  Google Scholar 

  42. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801–7.

    PubMed  CAS  Google Scholar 

  43. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 2005;23:2574–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, 1198 Guwol-dong, Namdong-gu, Incheon, 405-760, Korea

    Young Saing Kim, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Jae Hoon Lee & Dong Bok Shin

  2. Division of Hematology and Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Se Hoon Park

  3. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea

    Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park & Sung Hwan Jung

Authors
  1. Young Saing Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Se Hoon Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sun Young Kyung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sun Jin Sym
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sang Pyo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeong Woong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sung Hwan Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jinny Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eun Kyung Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jae Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dong Bok Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eun Kyung Cho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, Y.S., Park, S.H., Kyung, S.Y. et al. Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Med Oncol 28, 342–350 (2011). https://doi.org/10.1007/s12032-010-9453-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9453-z

Keywords

Search

Navigation